TherapeuticsMD (NASDAQ:TXMD – Get Free Report) and Addex Therapeutics (NASDAQ:ADXN – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.
Profitability
This table compares TherapeuticsMD and Addex Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| TherapeuticsMD | -6.64% | -1.09% | -0.78% |
| Addex Therapeutics | N/A | -174.44% | -126.47% |
Analyst Recommendations
This is a summary of current ratings for TherapeuticsMD and Addex Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| TherapeuticsMD | 1 | 0 | 0 | 0 | 1.00 |
| Addex Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| TherapeuticsMD | $3.27 million | 7.22 | -$570,000.00 | $0.02 | 102.00 |
| Addex Therapeutics | $29,972.00 | 128.66 | -$8.12 million | ($5.94) | -0.53 |
TherapeuticsMD has higher revenue and earnings than Addex Therapeutics. Addex Therapeutics is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.
Institutional and Insider Ownership
30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 16.1% of Addex Therapeutics shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by company insiders. Comparatively, 15.0% of Addex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility and Risk
TherapeuticsMD has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 1.52, meaning that its share price is 52% more volatile than the S&P 500.
Summary
TherapeuticsMD beats Addex Therapeutics on 7 of the 11 factors compared between the two stocks.
About TherapeuticsMD
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.
About Addex Therapeutics
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.
